The motivation to get vaccinated does not come as a surprise. 48 percent state they are at risk, 46 percent want to protect others and 41 percent simply want to protect themselves from the virus. Only 18 percent indicate it would be easier to travel when vaccinated. The most frequent chronic conditions among the respondents are Type 2 diabetes (24%), asthma (19%), multiple sclerosis (15%) and COPD (14%). Given the severity of these illnesses, it is surprising that a mere 67 percent in France and 47 percent in Germany do not intend to get vaccinated.
Michael Chekroun, Chief Strategy and Transformation Officer of the EvidentIQ group and Founder of Carenity explains these results:
“When it comes to the COVID-19 vaccines, nearly half of our respondents are afraid of side effects. Another 45 percent name the lack of information as reason for their reluctance to be vaccinated. To some extent this is understandable.”
Chekroun refers to the comparably short development and trial phases of the new vaccines. For these highly regulated trial processes imposed by public entities like EMA and FDA – EvidentIQ provides software infrastructure, scientific services and even access to patients to secure and automate testing procedures.
“Many people are not aware that for extraordinary situations like these there have always been Accelerated Approval Programs to shorten time-to-market for a new treatment. This is obviously where chronic patients are understandably nervous, fearing side effects and requiring more information. Our survey shows that only 4 percent of all respondents generally oppose vaccination.”
Medical visits or surgeries cancelled or postponed
Also, the survey shows that 46 percent report that medical visits or procedures have been canceled or postponed in the first wave of COVID-19, while 75 percent report the same for wave 2.
This may explain why roughly 67 percent of patients in the US are open to the use of telehealth consultations, in Europe only 47 percent.
The full interview with Michael Chekroun on the outcome of this survey and a free copy of the complete results are available under: https://www.linkedin.com/…
EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio such as patient recruitment, patient engagement media and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing and reimbursement needs.
EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China.
EvidentIQ Group GmbH
Rathausmarkt 5
20095 Hamburg
Telefon: +49 (89) 4522775000
Telefax: +49 (89) 4522775900
https://evidentiq.com
Marketing Manager
Telefon: +49 89 4522775-250
E-Mail: sabine.birkner@evidentiq.com
